Neurocrine Biosciences
NBIX
#1676
Rank
HK$102.69 B
Marketcap
HK$1,023
Share price
1.89%
Change (1 day)
10.57%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2024: HK$4.79 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are HK$2.68 Billion. In 2024 the company made an earning of HK$4.79 Billion, an increase over its 2023 earnings that were of HK$2.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2024

Annual earnings

Year Earnings Change
2024HK$4.79 B96.41%
2023HK$2.43 B41.13%
2022HK$1.72 B73.74%
2021HK$0.99 B-8.82%
2020HK$1.09 B77.78%
2019HK$0.61 B49.83%
2018HK$0.40 B-142.57%
2017-HK$0.97 Billion-14.73%
2016-HK$1.13 Billion53.15%
2015-HK$0.74 Billion46.25%
2014-HK$0.51 Billion29.66%
2013-HK$0.39 Billion-3530.8%
2012HK$11.32 M-95.73%
2011HK$0.26 B
2009-HK$0.38 Billion-45.38%
2008-HK$0.69 Billion-58.87%
2007-HK$1.67 Billion87.3%
2006-HK$0.89 Billion351.97%
2005-HK$0.2 Billion-52.09%
2004-HK$0.41 Billion-10.98%
2003-HK$0.46 Billion
2001-HK$0.35 Billion
1999-HK$0.16 Billion108.32%
1998-HK$74.32 Million
1996HK$22.68 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
HK$92.71 B 1,932.24%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$12.98 B 184.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$176.03 B 3,758.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$0.20 B-95.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$0.33 Billion-107.16%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$0.39 B-91.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$37.51 Million-100.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$12.37 B 171.24%๐Ÿ‡ฌ๐Ÿ‡ง UK